Whooping cough

Lore & Background

Whooping cough begins with mild respiratory symptoms similar to the common cold, including runny nose, fever, and mild cough. After one to two weeks, the cough develops into uncontrollable fits, sometimes followed by a high-pitched 'whoop' as the person inhales. About 50% of children and adults whoop at some point during the paroxysmal stage, which usually lasts up to three months. The violent coughing can cause fatigue, vomiting, rib fractures, subconjunctival hemorrhages, and even pneumothorax. In children less than one year old, the cough may be absent, replaced by periods of inability to breathe.

Reader's Guide

Whooping cough remains a major public health challenge despite widespread vaccination. The disease is spread easily through coughs and sneezes, and infected individuals are contagious from the start of symptoms until about three weeks into the coughing fits. Prevention primarily relies on vaccination, with initial immunization recommended between six and eight weeks of age and four doses in the first two years. Protection wanes over time, so additional doses are often recommended for older children and adults, and vaccination during pregnancy is highly effective at protecting infants. Antibiotics such as erythromycin, azithromycin, clarithromycin, or trimethoprim/sulfamethoxazole are useful if started within three weeks of symptom onset, but have little effect otherwise. About 50% of infected children under one year require hospitalization, and nearly 0.5% die. The disease persists in vaccinated populations due to waning immunity and bacterial mutations, with adolescents and adults acting as reservoirs for the bacterium.

Did You Know?

• The cough from pertussis can cause rib fractures, subconjunctival hemorrhages, and vertebral artery dissection.
• About 50% of infected children less than a year old require hospitalization, and nearly 0.5% die.
• Vaccination during pregnancy is highly effective at protecting the infant from pertussis during their vulnerable early months.

The Clinical Journey: From Cold to Coughing Fits

The clinical journey of pertussis unfolds in distinct phases spanning months. It opens with what resembles an ordinary cold—sneezing, a runny nose, mild fever, and a gentle cough—lasting roughly one to two weeks. This catarrhal phase then gives way to the paroxysmal stage, where the cough escalates into violent, uncontrollable fits. As the person struggles to draw air back in, a characteristic high-pitched whoop or gasp may sound; roughly half of diagnosed children and adults experience this at some point. The force of these episodes is remarkable: they can trigger vomiting, fatigue, subconjunctival hemorrhages, rib fractures, urinary incontinence, hernias, and in extreme cases a ruptured pleura leading to pneumothorax. A gradual convalescent stage follows, spanning one to four weeks, though paroxysms may linger for months if a secondary respiratory infection strikes. Infants under one year present differently, often showing little cough at all and instead suffering dangerous breathing pauses. The incubation window averages seven to fourteen days, though it can stretch to twenty or, rarely, forty-two days.

The Bacterium and Its Toxins

Bordetella pertussis is a bacterium with a singularly human obsession. Humans are its only natural host, and the organism spreads effortlessly through airborne droplets expelled by coughs and sneezes. Once inhaled, the bacteria latch onto the ciliated epithelial lining of the nasopharynx, using surface proteins such as filamentous hemagglutinin and pertactin to secure their grip. They then multiply, and in vulnerable infants the infection can descend into the lungs. The real damage comes from the toxins the bacterium secretes. Tracheal cytotoxin, a peptidoglycan fragment, destroys the ciliated cells responsible for clearing mucus and debris from the airways, a process that likely fuels the relentless cough. A separate pertussis toxin triggers lymphocytosis through a mechanism that remains unclear; the resulting white blood cell surge can drive pulmonary hypertension, a leading cause of pertussis-related death. In infants who develop encephalopathy, hypoxia leads to cerebral hemorrhage and cortical atrophy. The disease is so tightly bound to humans that even rare cases in zoo chimpanzees and wild gorillas are attributed to close human contact, prompting some zoos to vaccinate their primates. Diagnosis relies on a sample from the back of the nose and throat, tested by culture or polymerase chain reaction.

Vaccination, Antibiotics, and the Limits of Treatment

Vaccination remains the cornerstone of pertussis defense. The standard schedule calls for initial immunization between six and eight weeks of age, followed by a total of four doses within the first two years of life. Because immunity wanes over time, booster doses are recommended for older children and adults. A particularly important strategy is vaccinating during pregnancy, which is highly effective at shielding the newborn during those vulnerable early months. Antibiotics play a secondary but vital role. For exposed individuals at risk of severe disease, prophylactic antibiotics can prevent infection. In those already ill, antibiotics are beneficial if administered within three weeks of symptom onset; for pregnant women and infants under one year, the window extends to six weeks. The drugs most commonly prescribed include erythromycin, azithromycin, clarithromycin, and trimethoprim-sulfamethoxazole. Beyond antibiotics, the evidence base for treating the cough itself is notably weak. The stakes are highest for the youngest patients: roughly half of infected children under one year require hospitalization, and nearly one in two hundred succumb to the disease. Even vaccinated individuals who contract pertussis typically experience milder symptoms, though they remain capable of transmitting the infection to others who lack immunity.

A Global Burden Across the Centuries

The story of pertussis stretches back to the sixteenth century, when physicians first documented outbreaks of the devastating cough. The turning point came in the 1940s with the arrival of the first pertussis vaccine, a development that reshaped the disease's trajectory over the following decades. Today, pertussis still claims a significant global toll. The disease does not discriminate by age; people of all ages can be affected. The infectious window is a critical epidemiological detail: an infected person can spread the disease from the very onset of symptoms until roughly three weeks into the coughing phase. Because vaccine-derived protection wanes over time, the ongoing vulnerability of unvaccinated or under-immunized infants remains a central concern in global public health.